Compare IAC/Interactivecorp (PPLI) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IAC/Interactivecorp vs Recursion Pharmaceuticals Inc — how do they compare? IAC/Interactivecorp trades at $40.87 (market cap $3.05B), while Recursion Pharmaceuticals Inc trades at $4.33 (market cap $2.14B). The key difference: IAC/Interactivecorp is the larger of the two by market cap, and IAC/Interactivecorp is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IAC/Interactivecorp for 79 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| PPLI | RXRX | |
|---|---|---|
Market Cap | $3.05B | $2.14B |
Volume | 931,019 | 30,789,535 |
Sector | Media | Health |
52-Week High | $47.62 | $6.79 |
52-Week Low | $31.52 | $2.84 |
Typical Hold Time | 79 Days | 23 Days |
Enterprise Value | $3.53B | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PPLI trades at $40.85, up 0.64% on the day, with a bullish technical signal from moving averages. The stock has shown volatile earnings, missing estimates in Q4 2025 and Q1 2026 but beating in Q2 2026. Recent news highlights potential M&A activity, with MGM Resorts considering a bid for the company after PPLI withdrew its own offer to buy MGM, driving significant price movement. Valuation ratios appear attractive with a P/E of 6.92 and P/B of 0.6, though profitability metrics are mixed amid revenue declines from $5.2B in 2022 to $2.4B in 2025.
The outlook is cautiously optimistic due to strong analyst support (71.43% buy ratings) and speculative M&A upside, but risks include inconsistent earnings, high debt levels, and competitive pressures in the media sector. Net cash flow turned deeply negative in 2025 at -$820.42M, underscoring financial volatility. Investors should weigh the low valuation against execution challenges and industry headwinds.
RXRX trades at $4.255, down 0.35% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $644.76 million in 2025 on $74.26 million revenue, with a negative net income margin of -961.97%. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI announced September 21, 2026, and pipeline progress presented at the Morgan Stanley Healthcare Conference.
The outlook remains speculative, driven by AI-powered drug discovery potential and partnership milestones, but significant execution risk persists due to heavy losses and high cash burn. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for long-term platform value against near-term financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About IAC/Interactivecorp
IAC Inc is an Internet media company with segments that include Angi (47% of total revenue), Dotdash (10%), search (24%), and emerging and other (19%). The firm spun off the narrow-moat dating app provider Match Group in second-quarter 2020 and the no-moat video software provider Vimeo in second-quarter 2021.
Read more on PPLI →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
